Urinary oxalate excretion during anti-androgenic therapy.
We studied urinary oxalate excretion in three groups of patients with prostatic carcinoma who were treated with orchiectomy, estrogen, and cyproterone acetate, respectively. Urinary oxalate and plasma testosterone were analyzed before treatment and after 2 and 8 weeks of treatment. Despite a decrease in plasma testosterone concentration no significant change in oxalate excretion was detected in any group.
D000368:Aged; D002369:Castration; D003534:Cyproterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017373:Cyproterone Acetate; D004958:Estradiol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004997:Ethinyl Estradiol / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009943:Organophosphorus Compounds / Q000627:therapeutic use; D010070:Oxalates / Q000652:urine*; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000628:therapy*; D013739:Testosterone / Q000097:blood
D009943:Organophosphorus Compounds; D010070:Oxalates; D013739:Testosterone; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate; D004958:Estradiol; D003534:Cyproterone; C008958:polyestradiol phosphate